Drilldown: Medicines
Medicines > classes 
:
Anticonvulsant or
Sedative-Hypnotic or
[[:Category:Mood_stabilizers|Mood stabilizer]]
:
Anticonvulsant or
Sedative-Hypnotic or
[[:Category:Mood_stabilizers|Mood stabilizer]] Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
AMPA receptor antagonist (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (16) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (3) ·
GABAB agonist; GHB receptor agonist (1) ·
Irreversible GABA-T inhibitor (1) ·
Melatonin receptor agonist (2) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1) ·
'"`UNIQ--vote-00000975-QINU`"' Hyperammonemic encephalopathy (consider in any unexplained CNS depression), thrombocytopenia, and polycystic ovary syndrome are characteristic chronic-use adverse effects beyond hepatic and pancreatic risks'"`UNIQ--ref-00000976-QINU`"'. (1) ·
'"`UNIQ--vote-00001549-QINU`"' Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard'"`UNIQ--ref-0000154A-QINU`"'. (1)
uses:
None (48) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000977-QINU`"', '"`UNIQ--vote-00000978-QINU`"', '"`UNIQ--vote-00000979-QINU`"', '"`UNIQ--vote-0000097A-QINU`"', '"`UNIQ--vote-0000097B-QINU`"' (1) ·
'"`UNIQ--vote-0000154B-QINU`"', '"`UNIQ--vote-0000154C-QINU`"' (1)
starting dose:
None (48) ·
6/25 mg PO once daily in the evening; titrate within range 3/25 to 18/75 mg by clinical response and tolerability (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
Seizures: 10-15 mg/kg/d divided BID-TID, titrate to therapeutic level (50-100 mcg/mL); bipolar mania: 750 mg/d divided, titrate (1)
preparations:
None (48) ·
125, 250, 500 mg delayed-release tablets (Depakote); 250, 500 mg ER tablets (Depakote ER); 125, 250 mg sprinkle capsules; 250 mg/5 mL syrup; 500 mg IV (Depacon) (1) ·
Capsules: 3/25, 6/25, 6/50, 12/25, 12/50 mg olanzapine/fluoxetine (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (48) ·
Not formally characterized in humans. (1) ·
Olanzapine 60% (oral); fluoxetine high (oral)'"`UNIQ--ref-0000154E-QINU`"' (1) ·
~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)'"`UNIQ--ref-0000097D-QINU`"' (1)
pregnancy:
None (48) ·
'''Contraindicated for migraine prophylaxis in pregnancy; high teratogenic risk''' (neural tube defects, craniofacial anomalies, cardiac defects, cognitive/IQ impairment); avoid in women of childbearing potential without reliable contraception when alternatives exist'"`UNIQ--ref-0000097E-QINU`"' (1) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (49) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warnings''' for hepatotoxicity (especially children <2 with metabolic disorders), teratogenicity, and pancreatitis'"`UNIQ--ref-0000097F-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients'"`UNIQ--ref-0000154F-QINU`"' (1)
Showing below up to 51 results in range #1 to #51.